Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DxNA, llc. Announces New Equity Funding

Published: Monday, November 25, 2013
Last Updated: Monday, November 25, 2013
Bookmark and Share
DxNA, llc. announced the finalizing of an equity investment of $2.5 million by an individual investor.

The investment dollars will be used to complete the regulatory processes for the FDA 510(k) clearance of a Valley Fever (Coccidioidomycosis) assay on the GeneSTAT® system. The funding will also be used to initiate the regulatory processes for FDA 510(K) clearance and EEA CE-marking of a next-generation Staphylococcus Diagnostic Test the company calls its MRSA+ Assay.

The GeneSTAT® system is a rapid real-time PCR analyzer and cartridge system that is designed to be a simple to use, point of care system. The system has previously been validated for a CE-mark, which was obtained in 2011.

Valley Fever, called “A Silent Epidemic” by the CDC in a June 2013 article, is endemic to parts of California, Nevada, Utah, New Mexico, and Texas and the entire state of Arizona. As populations in those area increase and as more people travel through those areas, the exposure to and the risk of a significant number of infections is increasing each year. There are currently no FDA cleared PCR-based assays for diagnosing this disease that can be debilitating. Clearing this assay on a rapid, cost effective, point of care device will give the medical practitioner the option to quickly diagnose the symptomatic patient and prescribe appropriate monitoring and treatment before the disease reaches a debilitating stage.

The MRSA+ Assay, as previously mentioned, is a next generation Staphylococcus - assay that will detect and differentiate both Staphylococcus aureus and Coagulase Negative Staphylococcus in a sample and also detect which, if either, has the Methicillin resistant mec-A gene. On the GeneSTAT system this assay will, in about an hour, identify and differentiate infections caused by antibiotic resistant and/or non-resistant types of Staphylococcus thus providing information to the medical practitioner that is critical to treatment decisions that can save lives. This assay, upon regulatory clearance, is expected to be marketed in the United States as well as the EU.

“This funding is allowing us to press forward on the path we have been mapping out since we acquired the rights to both of these assays. This is an exciting time for DxNA, bringing us closer to entering the US and EU diagnostic markets with what we feel are ground breaking and distinguishing products.” says David Taus, CEO of DxNA, llc.

DxNA is a privately held company located in St. George Utah. It is a molecular diagnostics company that develops and distributes portable, fully-integrated systems and tests for infectious disease in the medical, agricultural, food safety, and biosecurity markets. The Company's systems and technologies enable rapid and precise molecular testing to take place on-site by allowing for otherwise complex laboratory procedures to be performed almost anywhere.

DxNA’s patented GeneSTAT® portable Real Time PCR molecular diagnostic testing system will allow individuals with minimal training to conduct accurate real-time diagnostic testing in virtually any location including laboratories, clinics, physician offices, emergency rooms or field settings. Designed with economy in mind, GeneSTAT is inherently less costly than the real time PCR systems typical of clinical laboratories.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DxNA to Acquire PathoGene
DxNA will acquire exclusive rights for Unit Dose Platform Applications of PathoGene’s multiplexed Staphylococcus MRSA+ assay on DxNA’s Real Time PCR GeneSTAT platform.
Monday, July 22, 2013
Scientific News
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Using Cancer Cells' Mass to Predict Treatment Response
A device has been developed that can detect changes in cell mass at a minute scale.
NVIDIA Awards $400k to Trailblazers in Cancer Research
NVIDIA Foundation furthers research that could lead to new and more targeted treatments with investments.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Working With Advanced Nanoimagers
Oxford Nanoimaging report on the work of early-adopters for their Nanoimager technology at the MRC Centre for Molecular Bacteriology and Infection.
History of Cells Told Through MEMOIR
MEMOIR technique developed by CalTech researchers enables the life history of cells to be read.
Nanoscale ‘Muscles’ Powered by DNA
Scientists have developed nanoscale "muscles" to integrate with custom DNA, that can force the material to bend, curl and flip.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Cancer Stem Cells Fuel Tumor Growth
Mass. General, Broad Institute team finds strong evidence that cancer stem cells are important drivers of tumors in patients.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!